Prognos Health Inc.

Prognos Health Inc. , based in New York, specializes in delivering advanced clinical and genomic laboratory data solutions for the life sciences industry, helping clients optimize treatment patterns and healthcare provider engagement. Founded in 2010, Prognos Health Inc. operates from its headquarters in New York, US.

The company focuses on integrating laboratory and health records to provide actionable insights for pharmaceutical companies. It has successfully completed nine deals, with its most recent funding round, Series I, raising USD 23. 29 mn on April 10, 2023, involving multiple investors including Cigna Ventures and Merck Global Health Innovation Fund. The company was founded by Destry Sulkes, with Sundeep Bhan currently serving as CEO.

Prognos Health specializes in providing clinical and genomic laboratory data solutions tailored for the life sciences industry. Their core offerings include comprehensive datasets that integrate lab and health records, serving over 325 million patients. These products are designed to empower pharmaceutical companies by delivering actionable insights derived from harmonized clinical data, thus facilitating the identification of appropriate healthcare providers (HCPs) and optimizing treatment patterns. Prognos Health’s products are utilized across various therapeutic areas, enabling clients to effectively educate HCPs on brand-eligible treatments before critical treatment decisions are made.

The company primarily serves clients within the United States, leveraging partnerships with numerous laboratories to maintain a robust, de-identified laboratory dataset that supports commercial analytics and real-world evidence generation. Prognos Health generates revenue through a subscription-based model that grants clients access to its extensive data offerings. Clients, which include pharmaceutical companies and healthcare organizations, engage in direct partnerships to utilize Prognos’ lab data for commercial analytics and marketing strategies. Standard transactions often involve tailored service agreements that allow clients to leverage Prognos’ real-world data capabilities, streamlining their analytical processes.

These partnerships facilitate rapid access to high-fidelity laboratory data, which enhances the clients' decision-making capabilities without the lengthy delays typically associated with data ingestion. Prognos’ flagship offerings include solutions focused on oncology and rare diseases, which are critical in addressing specific healthcare needs within their client base. Following the recent Series I funding round raising USD 23. 29 mn in April 2023, Prognos Health Inc.

plans to utilize these funds to accelerate business growth and expand its platform. The company is focusing on developing new products tailored to evolving market needs, with specific plans to enhance its offerings in oncology and rare diseases. Additionally, Prognos aims to expand into new geographic regions, targeting both domestic and international markets by the end of 2024. The funding will support these initiatives by enhancing their data analytics capabilities and fostering new partnerships within the healthcare sector.